Brain Tumour Treatment Is Set To Be Revolutionised By A Cheap Drug

A trio of medical experts from Manchester have made a potentially revolutionary breakthrough for the treatment of brain tumours.   Innovate Pharmaceuticals – led by Dr James Stuart, Simon Cohen and Jan Cohen – was part of the development team for a new drug, known as IP1867B. The pioneering medication could transform the future treatment of brain tumours.  The major cause of treatment failure in patients is resistance to targeted therapies and pre-clinical trials of the new drug have demonstrated its ability to sensitise tumours to the latest generation of treatments. Trials have even demonstrated a capacity for the drug to prevent tumours from acquiring resistance at all, which would dramatically improve the success of treatment for this particular cancer.


Our work on multiple disease areas in the cancer field has shown that hitting a number of targets with IP1867B allows us to not only shrink tumours but unmask them allowing other therapies to attack them, said Dr James Stuart, medical director at Eccles based Innovate Pharmaceuticals. “This action of ‘turning cold tumours hot’ alongside the reversal of acquired resistance, boosting combination efficacy and a possible lowering of side effect burden makes IP1867B a true breakthrough in cancer treatment. The next step is to take IP1867B into ‘first in human’ trial. We actively driving this next stage of development and look forward to seeing the results,” he explained.

Alongside Innovate Pharmaceuticals, trials were led by the research team at the Brain Tumour Research Centre at University of Portsmouth, working with the University of Liverpool and the University of Algarve in Portugal.  The success rate for cancer therapies has been limited due to a combination of factors, such as the tumour’s ability to hide from and develop resistance to the treatment; excessive side effects; the treatment not being clinically effective; and the lack of penetration through the blood brain barrierIP1867B was shown to be effective at targeting all of these limiting factors.  The research team worked with existing cancer treatments and combination studies with traditional chemotherapy, targeted therapies and immunotherapies are now underway.


Comments are closed.